Fluorescent HCMV Virus Assay for Antibody Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for screening potential HCMV vaccine candidates are time-consuming and inefficient, particularly in high-throughput applications, as they rely on quantifying nuclei of infected cells to determine the neutralization of viral entry, which is not suitable for rapid assessment of neutralizing antibody induction.
Innovation Solution
A method utilizing HCMV viruses engineered with a fluorescent moiety for detection of neutralizing antibodies, where the virus is pre-incubated with a test sample, and subsequent infection of host cells is assessed using fluorescence detection, allowing for rapid quantitation of infection levels and neutralizing antibody presence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional neutralization assays quantify nuclei of infected cells based on viral protein expression, then neutralizing antibody activity can be established, but the process becomes time-consuming and difficult to employ in high throughput applications
Solution Approach 1:
The patent replaces the traditional mechanical/cellular assay method (quantifying nuclei based on viral protein expression) with a fluorescent detection system. HCMV viruses are engineered to express fluorescent proteins, allowing direct optical detection of infected cells without requiring nuclear quantification or protein expression analysis, thereby enabling high-throughput screening while maintaining detection accuracy
Solution Approach 2:
The patent utilizes fluorescent proteins (color/optical changes) as reporters for viral infection. The HCMV virus is modified to express fluorescent markers, so that infected cells emit detectable fluorescence signals. This optical readout enables rapid, automated, high-throughput detection of neutralizing antibodies while preserving the biological relevance of the neutralization assay
2Productivity
If HCMV viruses are engineered with fluorescent moieties for detection, then high throughput screening becomes feasible, but the virus modification complexity increases
Solution Approach 1:
The fluorescently engineered HCMV virus serves multiple functions: it maintains infectivity for neutralization assays, provides direct optical detection capability, and enables high-throughput screening. The single modification (adding fluorescent protein expression) delivers multiple benefits including simplified detection, increased throughput, and preserved biological function, making the added complexity worthwhile
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables a more efficient and high-throughput method for determining neutralizing antibody levels, correlating fluorescence detection with viral infection, thereby assessing the efficacy of vaccine-induced immune responses effectively.
Implementation Method 1
HCMV viruses that include a fluorescent moiety permit detection of viral infection
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides methods useful for determining levels of HCMV infection in host cells and, by extension, determining levels of neutralizing antibodies present in a sample. The present disclosure encompasses the recognition that HCMV viruses that have a fluorescent moiety permit detection of viral infection (e.g., by assessing fluorescence in cells after contacting the host cell with the virus). In some embodiments, levels of HCMV infection are determined by fluorescence detection where the virus has been preincubated with a test sample (e.g., a serum sample) from a subject. In some embodiments, the subject has been administered a candidate HCMV vaccine.